Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine as First Line Treatment in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC). A Prospective , Multicenter, Randomized, Phase III Trial

NCT00441740 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.

NCT NCT00441740
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00441740 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine as First Line Treatment in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC). A Prospective , Multicenter, Randomized, Phase III Trial
Lead sponsor
Hellenic Oncology Research Group
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2004
Completion date
February 29, 2008
Enrollment
419 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer